Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Completed · Phase 1
Conditions studied: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving panobinostat together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with everolimus in treating patients with relapsed or refractory lymphoma or multiple myeloma.
Key facts
- Study ID
- NCT00962507
- Run by
- City of Hope Medical Center
- People needed
- 11
- Starts
- 2009-07-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2013-02-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Medical Center — Duarte, California, United States
- City of Hope Medical Group — Pasadena, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.